Protagenic Therapeutics, Inc.\new Current Ratio Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's current ratio was 1.50 for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | 1.50 | 1.48 | +8363.55% |
| 2025 | 2025-03-31 | 0.02 | — | — |
| 2024 | 2024-12-31 | 2.00 | −4.41 | −68.84% |
| 2023 | 2023-12-31 | 6.41 | −0.77 | −10.67% |
| 2022 | 2022-12-31 | 7.18 | −6.66 | −48.13% |
| 2021 | 2021-12-31 | 13.83 | 12.49 | +930.79% |
| 2020 | 2020-12-31 | 1.34 | 0.64 | +90.83% |
| 2019 | 2019-12-31 | 0.70 | −0.06 | −8.31% |
| 2018 | 2018-12-31 | 0.77 | −2.40 | −75.80% |
| 2017 | 2017-12-31 | 3.17 | −1.45 | −31.34% |
| 2016 | 2016-12-31 | 4.62 | 4.61 | +93553.01% |
| 2015 · Dec 31 | 2015-12-31 | 0.00 | — | — |
| 2015 · Jun 30 | 2015-06-30 | 0.70 | −1.04 | −59.81% |
| 2014 | 2014-06-30 | 1.74 | — | — |
Protagenic Therapeutics, Inc.\new quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | 0.66 | 0.25 | +59.87% |
| Q4 2026 | 2026-03-31 | 1.50 | 1.48 | +8363.55% |
| Q3 2026 | 2025-12-31 | 0.34 | −1.66 | −83.13% |
| Q2 2026 | 2025-09-30 | 0.29 | −1.51 | −83.66% |
| Q1 2026 | 2025-06-30 | 0.41 | −1.62 | −79.60% |
| Q4 2025 | 2025-03-31 | 0.02 | −5.51 | −99.68% |
| Q4 2024 | 2024-12-31 | 2.00 | −4.41 | −68.84% |
| Q3 2024 | 2024-09-30 | 1.80 | −2.40 | −57.09% |
| Q2 2024 | 2024-06-30 | 2.03 | −2.57 | −55.84% |
| Q1 2024 | 2024-03-31 | 5.53 | −0.59 | −9.64% |
| Q4 2023 | 2023-12-31 | 6.41 | −0.77 | −10.67% |
| Q3 2023 | 2023-09-30 | 4.20 | −10.71 | −71.84% |
| Q2 2023 | 2023-06-30 | 4.60 | −14.87 | −76.39% |
| Q1 2023 | 2023-03-31 | 6.12 | −6.38 | −51.04% |
| Q4 2022 | 2022-12-31 | 7.18 | −6.66 | −48.13% |
| Q3 2022 | 2022-09-30 | 14.91 | −1.18 | −7.32% |
| Q2 2022 | 2022-06-30 | 19.47 | −0.55 | −2.75% |
| Q1 2022 | 2022-03-31 | 12.50 | 12.20 | +4049.74% |
| Q4 2021 | 2021-12-31 | 13.83 | 12.49 | +930.79% |
| Q3 2021 | 2021-09-30 | 16.09 | 14.68 | +1043.71% |
| Q2 2021 | 2021-06-30 | 20.02 | 18.53 | +1248.03% |
| Q1 2021 | 2021-03-31 | 0.30 | −0.65 | −68.39% |
| Q4 2020 | 2020-12-31 | 1.34 | 0.64 | +90.83% |
| Q3 2020 | 2020-09-30 | 1.41 | 0.97 | +219.25% |
| Q2 2020 | 2020-06-30 | 1.48 | 1.01 | +210.01% |
| Q1 2020 | 2020-03-31 | 0.95 | 0.39 | +69.72% |
| Q4 2019 | 2019-12-31 | 0.70 | −0.06 | −8.31% |
| Q3 2019 | 2019-09-30 | 0.44 | −1.04 | −70.28% |
| Q2 2019 | 2019-06-30 | 0.48 | −1.57 | −76.63% |
| Q1 2019 | 2019-03-31 | 0.56 | −2.35 | −80.71% |
| Q4 2018 | 2018-12-31 | 0.77 | −2.40 | −75.80% |
| Q3 2018 | 2018-09-30 | 1.48 | −2.65 | −64.11% |
| Q2 2018 | 2018-06-30 | 2.05 | −2.19 | −51.70% |
| Q1 2018 | 2018-03-31 | 2.91 | −1.76 | −37.66% |
| Q4 2017 | 2017-12-31 | 3.17 | −1.45 | −31.34% |
| Q3 2017 | 2017-09-30 | 4.13 | −1.40 | −25.29% |
| Q2 2017 | 2017-06-30 | 4.24 | −2.04 | −32.43% |
| Q1 2017 | 2017-03-31 | 4.67 | −0.42 | −8.33% |
| Q4 2016 | 2016-12-31 | 4.62 | 4.61 | +93553.01% |
| Q3 2016 | 2016-09-30 | 5.53 | 5.45 | +7089.82% |
| Q2 2016 | 2016-06-30 | 6.28 | 5.58 | +799.36% |
| Q1 2016 · Mar 31 | 2016-03-31 | 5.10 | 4.85 | +2001.19% |
| Q4 2015 · Dec 31 | 2015-12-31 | 0.00 | −0.44 | −98.88% |
| Q1 2016 · Sep 30 | 2015-09-30 | 0.08 | −0.49 | −86.34% |
| Q4 2015 · Jun 30 | 2015-06-30 | 0.70 | −1.04 | −59.81% |
| Q3 2015 | 2015-03-31 | 0.24 | — | — |
| Q2 2015 | 2014-12-31 | 0.44 | — | — |
| Q1 2015 | 2014-09-30 | 0.56 | — | — |
| Q4 2014 | 2014-06-30 | 1.74 | — | — |
| As of Sep 30, 2011 | 2011-09-30 | 0.48 | — | — |
| As of Jun 30, 2011 | 2011-06-30 | 0.56 | — | — |
Protagenic Therapeutics, Inc.\new current ratio trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's current ratio decreased from 1.74 to 1.50, a change of −0.24. The latest reported quarter, Q1 2027, shows 0.66.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗